OS Therapies (OSTX) raises up to $8M via warrant exercise inducement; extends cash runway into H2 2026

OS Therapies Inc

Holders exercise 1.57M old warrants ($1.12) for cash; receive new 5-year warrants at $3.00/sh.
Gross proceeds up to ~$8M; $1.76M already received, extending cash runway into H2 2026.
Proceeds to support regulatory/pre-commercial efforts for OST-HER2 in osteosarcoma.
Offering period June 20 to July 10, 2025; solicitation agent fee 5% of gross proceeds.
Company reiterates BLA submission to FDA in Q3 2025; potential PRV sale (most recent at $160M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.